|
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081
INVENTORS
Sarki Abdulkadir (PI)*
Gary Schiltz (PI)*
SHORT DESCRIPTION
A small molecule PROTAC technology that degrades DOT1L protein for targeted treatment of leukemia and prostate cancer.
BACKGROUND
Current cancer treatments, especially for MLL-rearranged leukemia and prostate cancer, face challenges of off-target effects and...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Leukemia, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|